Predictive value of metabolic activity detected by pre-operative $^{18}$F FDG PET/CT in ampullary adenocarcinoma

Young Mok Park, MD* ‡, Hyung Il Seo, MD, PhD

Abstract
In ampullary adenocarcinoma cases, the clinical effects of $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) have not yet been well-studied, unlike other prognostic factors that have been reported till date. This study aimed to investigate the clinical impact of maximum standardized uptake value (SUVmax) in predicting the prognosis of ampullary adenocarcinoma.

Thirty-eight patients who underwent pre-operative $^{18}$F-FDG PET/CT and curative-intent resection of ampullary adenocarcinoma at Pusan National University Hospital (Pusan, South Korea) between 2008 and 2017 were retrospectively analyzed in this study. We evaluated the clinicopathologic outcomes according to the SUVmax using univariate and multivariate Cox proportional hazard regression analyses and receiver operating characteristic analysis to arrive at a cutoff value.

Lymph node metastasis was detected in 9 patients, and 15 patients experienced a recurrence during the follow-up period. Among 38 patients, 33 showed an increased FDG uptake by the main tumor. SUVmax of 4.55 was selected as a significant independent predictive factor for patient survival along with poor tumor differentiation and high neutrophil-to-lymphocyte ratio in multivariate analysis ($P$ = .016, hazard ratio = 5.040). Patients with SUVmax under 4.55 exhibited significantly longer overall survival than the rest ($<4.55$ vs $\geq 4.55$), and the 5-year overall survival was 82.8% versus 57.4% ($P$ = .049).

SUVmax of 4.55 on $^{18}$F-FDG PET/CT could be a predictive factor for tumor biology and long-term survival in patients with ampullary adenocarcinoma. Nevertheless, considering the cost aspect and its limited prognostic effect, this study seems to require more patient and multicenter studies.

Abbreviations: CRP = C-reactive protein, CT = computed tomography, DFS = disease-free survival, FDG = fluorodeoxyglucose, HR = hazard ratio, NL = neutrophil-to-lymphocyte, OS = overall survival, PET = positron emission tomography, PL = platelet-to-lymphocyte, PNL = platelet-neutrophil-lymphocyte, ROC = receiver operating characteristic, SUVmax = maximum standardized uptake value.

Keywords: ampullary adenocarcinoma, $^{18}$F-fluorodeoxyglucose positron emission tomography, prognosis, standardized uptake value

1. Introduction

Ampullary adenocarcinoma is a type of periampullary cancer that accounts for 0.2% of gastrointestinal malignancies and 6% of periampullary cancers.[1,2] Ampullary adenocarcinoma has a better prognosis than other periampullary cancers. Compared to other periampullary cancers, ampullary adenocarcinoma tends to be detected relatively early. Therefore, ampullary adenocarcinomas have a higher resection rate at the time of diagnosis. Stage I is most frequently seen in these cancers (21.2%–56.3%), and the overall 5-year survival rate has been reported to be between 40% and 61.3%. The survival rates decrease with increasing pathologic stage.[3–11] Surgical resection is the only potentially curative treatment for patients with ampullary adenocarcinoma. Several prognostic factors, including T category, nodal metastasis, lymphovascular invasion, perineural invasion, blood transfusion, serum carbohydrate antigen 19–9, and loss of body mass index >4%, have been previously reported.[10–17]

Currently, $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography ($^{18}$F-FDG PET/CT) is widely used to assess many different types of malignancies, and the maximum standardized uptake value (SUVmax) can be used to predict the survival of patients with malignancy. The extent of the uptake of $^{18}$F-FDG by cancer that usually correlates with a prognostic impact has shown variable results and is debatable. Recently, a study reported that high SUVmax ($>7.5$) could be a prognostic factor for overall survival (OS) and disease-free survival (DFS) in ampullary adenocarcinoma.[18] The objective of this study was to assess the prognostic value of pre-operative $^{18}$F-FDG PET/CT according to metabolic activity and to investigate the clinicopathological differences in this metabolic activity in ampullary adenocarcinoma.
2. Patients and methods

2.1. Patients

A total of 66 patients who underwent curative resection for ampullary adenocarcinoma at Pusan National University Hospital (Pusan, South Korea) from January 2008 to December 2017 were enrolled in this study. A retrospective review was performed based on medical records. Patients who did not undergo pre-operative 18F-FDG PET/CT were excluded, as well as patients with other types of periampullary carcinoma and non-invasive carcinoma (high grade dysplasia or carcinoma in situ, papillary adenocarcinoma). Finally, 38 patients were included. This retrospective study was approved by the institutional review board at Clinical Trial Center (Institutional review board number: 2003-022-089) and written informed consent was obtained from all participants. The clinical information retrospectively reviewed from the patient medical records is shown in Table 1.

2.2. 18F-FDG PET/CT

All patients underwent fasting for at least 8 hours to ensure a serum glucose level of less than 120 mg/dL. PET/CT imaging was performed 60 minutes after the injection of 18F-FDG (5.18 MBq/kg). All scans were performed utilizing one of the 2 systems (Biograph from Siemens Medical Solution, Hoffman Estates, IL, or Gemini from Philips Medical Systems, Cleveland, OH) using 3-dimensional mode with an acquisition time of 3 minutes per bed position from the base of the skull to the proximal thigh. For a quantitative analysis of the 18F-FDG uptake, a region of interest was placed over the most intense area of 18F-FDG uptake. The activity concentration within this region was determined and expressed as the standardized uptake value, which was calculated as follows: standardized uptake value = region’s radioactivity concentration (Bq/mL)/[injected dose (Bq)/patient’s weight (g)].

2.3. Statistical analysis

We analyzed clinicopathological features, DFS, and OS rates. OS rate was measured from the date of surgery to the date of death from any cause; locoregional recurrences, distant metastases, and second primary cancer were ignored. DFS rate was measured from the date of surgery to the date of second cancer, locoregional recurrence, distant metastases, or death from any cause. The cutoff value of SUVmax was determined by receiver operating characteristic (ROC) curve analysis. Through ROC curve, the optimal value of SUVmax was identified. SUVmax (4.55) was selected as optimal cutoff value for quantitative SUVmax. The SUVmax from 18F-FDG PET/CT and other tumor factors were compared between the following 2 subgroups using the chi-square test: High metabolism group (SUVmax ≥ 4.55) and low metabolism group (SUVmax < 4.55). The chi-square test was used to compare all categorical variables. OS and DFS were estimated according to the Kaplan-Meier method, and survival differences were evaluated using the log-rank test. Both univariate and multivariate Cox proportional hazard regression models were used to identify risk factors for recurrence or death. Risk factors obtained from univariate models were included in the multivariate models. All statistical analyses were performed using SPSS software (version 20.0; SPSS Inc, Chicago, IL), and P values <.05 were considered statistically significant.

3. Results

3.1. Patient characteristics

The study cohort consisted of 21 men and 17 women. The median age was 64 years (range, 32–85). There were 24 patients with T1 and T2 tumors (63.1%), and lymph node metastases were detected in 8 patients. The median number of retrieved lymph node was 20.7 (range, 4–67). According to the 7th edition of the cancer staging manual by American Joint Committee on Cancer, 14 patients (36.8%) were classified as Stage I, 7 (18.4%) were classified as Stage II, 9 (23.7%) were classified Stage III, and 8 (21.1%) classified as Stage IIB. Adjuvant treatment was administered to 7 patients (5 received concomitant chemoradiation therapy and 2 received only chemotherapy) with lymph node metastases (Table 1).

3.2. SUVmax according to patient clinicopathological characteristics

The cutoff value of SUVmax was determined by an ROC curve analysis. According to the ROC curve, the SUVmax cutoff value for patient’s survival was 4.55, and the sensitivity and specificity were 61.5% and 60.0% (95% confidence intervals:

---

Table 1
Clinicopathological characteristics of patients with ampullary adenocarcinoma.

| Variables                        | Number of patients, (%) |
|----------------------------------|-------------------------|
| Sex                              |                         |
| Male                             | 21 (55.3)               |
| Female                           | 17 (44.7)               |
| Median age (age range), yrs      | 64.5 (32–85)            |
| Comorbidity                      |                         |
| Diabetes                         | 8                       |
| Hypertension                     | 13                      |
| Cardiovascular disease           | 4                       |
| Dementia                         | 1                       |
| Pulmonary disease                | 2                       |
| Other cancer operation           |                         |
| CEA (range), nm/L                | 2.31 (0.73–24.47)       |
| CA19-9 (range), U/mL             | 61.01 (0.6–3019)        |
| Albumin (range), mg/dL           | 3.95 (2.4–4.8)          |
| CRP (range), mg/dL               | 1.01 (0.05–14.52)       |
| T stage                          |                         |
| T1                               | 14 (36.8)               |
| T2                               | 10 (26.3)               |
| T3                               | 14 (36.8)               |
| Lymph node metastases            |                         |
| Yes                              | 8 (21.1)                |
| No                               | 30 (78.9)               |
| Tumor size (range), cm           | 2.2 (0.5–5.5)           |
| Perineural invasion              |                         |
| Yes                              | 9 (23.7)                |
| No                               | 29 (76.3)               |
| Lymphovascular invasion          |                         |
| Yes                              | 9 (23.7)                |
| No                               | 29 (76.3)               |
| Differentiation                  |                         |
| Well                             | 10 (26.3)               |
| Moderate                         | 19 (50.0)               |
| Poor                             | 9 (23.7)                |
| Adjuvant treatment               | 7 (18.4)                |

CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen, CRP = C-reactive protein, Other cancer operation = stomach cancer, sarcoma, and bladder cancer, T stage = according to AJCC 7th.
0.431–0.828), respectively (Fig. 1). For disease recurrence, there were no statistical significances of SUVmax. OS difference was observed with an SUVmax cutoff value of 4.55, and the 1-, 3-, and 5-year OS rates based on an SUVmax of 4.55 in the 2 groups were 100%, 89.2%, and 82.8%, respectively versus 94.1%, 63.7%, and 57.4%, respectively. Patients with SUVmax < 4.55 had a significantly longer survival ($P = .049$) (Fig. 2). Patient characteristics according to metabolic activity are shown in Table 2. Patients with SUVmax ≥ 4.55 had higher platelet-neutrophil-lymphocyte (PNL) ratio ($P = .05$), larger tumor size ($P = .02$), more advanced T stage ($P = .02$), lymph node metastases ($P = .01$), and lymphovascular invasion ($P = .04$). PNL ratio, tumor size, T state, nodal status, and lymphovascular invasion are well-known significant prognostic factors for periampullary adenocarcinoma.

### 3.3. Patient survival and disease recurrence

Of the 38 patients enrolled in this study, 15 patients experienced a recurrence (4 had locoregional, 4 liver, 3 lung, 3 peritoneum, and 1 bone) during the clinical follow-up period after curative resection. One patient died without a recurrence. The median duration of follow-up after surgery was 54 months. The 5-year OS rate after surgery was 70.9% (Fig. 3A), and the 5-year DFS rate was 62.0% (Fig. 3B).

We performed univariate analysis to evaluate the relationship between the clinicopathological variables and OS. This analysis revealed that patient survival was associated with histologic differentiation, T stage, nodal status, lymphovascular invasion, PL ratio, NL ratio, and PNL ratio. Among these factors, the cutoff level of quantitative values such as PL, NL, and PNL ratio were PL (163, 76.9% and 64.0%), NL (3.5, 76.9% and 72.0%), and PNL (951, 76.9% and 72.0%). In the subsequent multivariate analysis, we found that poor histologic differentiation, high SUVmax, and NL ratio were independent risk factors for patient survival ($P = .004$, hazard ratio [HR] = 6.560, $P = .016$, HR = 5.040 and $P = .003$, HR = 7.658, respectively) (Table 3).

We also performed univariate analysis to evaluate the relationship between the clinicopathological variables and disease recurrence. This revealed that DFS was associated with histologic differentiation, T stage, nodal status, lymphovascular invasion, NL ratio, and PNL ratio. In the multivariate analysis, poor histologic differentiation and NL ratio were the statistically significant risk factors for disease recurrence ($P = .027$, HR = 3.328, $P = .018$, HR = 4.245, respectively) (Table 3).

### 3.4. Clinical course of PET-negative patients

PET negative findings in periampullary adenocarcinoma has been known as a good prognostic factor, but there may be some cases that give different results than expected. Table 3 showed that among 38 patients, 5 patients exhibited no FDG uptake (PET-negative) in the cancer lesion on $^{18}$F-FDG PET/CT. The 5-year OS rate was 80.0%, and the 5-year DFS rate was 80% in these PET-negative patients. There was no survival difference between PET-negative and PET-positive patients. Among 5 patients, only 2 cases of death were seen. The case 4 with bone metastasis had several poor prognostic factors such as poor tumor differentiation, high NL. The patient received radiotherapy for bone metastasis but died because of sepsis after 2 months. But the case 3 patient did not have another factors that could make the prognosis worse. She was found to have lymph node metastases in Roux-en-Y jejunal limb and received multimodal treatments, including palliative concomitant chemoradiation therapy, pallia-
tive chemotherapy, and radiofrequency ablation. She died because of aggravating liver and lung metastases at 111 months postoperatively (Table 3).

### 4. Discussion

In the present study, we evaluated the significance of SUVmax measured by pre-operative 18F-FDG PET/CT for predicting the prognosis of patients with ampullary adenocarcinoma. Our results demonstrate that SUVmax of 4.55 on 18F-FDG PET/CT could be a predictive factor for tumor biology and long-term survival in patients with ampullary adenocarcinoma.

Although better than other periampullary adenocarcinomas, the prognosis of ampullary adenocarcinoma still remains poor. Recurrence rate approaches 40% and 5-year OS ranges from 33% to 68%. Our study results were concurrent with the

| Characteristic | No. | SUVmax < 4.55 n = 20, (%) | SUVmax ≥ 4.55 n = 18, (%) | P value |
|---------------|-----|--------------------------|---------------------------|---------|
| Age, yrs |
| < 65 | 19 | 10 (50.0) | 9 (50.0) | .94 |
| ≥ 65 | 19 | 10 (50.0) | 9 (50.0) | |
| Sex |
| Male | 21 | 9 (45.0) | 12 (66.7) | .18 |
| Female | 17 | 11 (55.0) | 6 (33.3) | |
| CEA, ng/mL |
| < 5 | 28 | 15 (93.8) | 13 (76.5) | .17 |
| ≥ 5 | 5 | 1 (20.0) | 4 (27.8) | |
| CA19-9, U/mL |
| < 39 | 15 | 9 (52.9) | 6 (33.3) | .24 |
| ≥ 39 | 20 | 8 (47.1) | 12 (66.7) | |
| Albumin, mg/dL |
| < 3.5 | 6 | 4 (52.9) | 2 (11.1) | .19 |
| ≥ 3.5 | 32 | 16 (47.1) | 16 (88.9) | |
| CRP, mg/dL |
| < 1.0 | 19 | 10 (50.0) | 9 (50.0) | 1.00 |
| ≥ 1.0 | 19 | 10 (50.0) | 9 (50.0) | |
| GPS |
| 0 | 18 | 10 (50.0) | 8 (44.4) | .73 |
| 1–2 | 20 | 10 (50.0) | 10 (55.6) | |
| mGPS |
| 0 | 19 | 10 (50.0) | 9 (50.0) | 1.00 |
| 1–2 | 19 | 10 (50.0) | 9 (50.0) | |
| PL ratio |
| < 163 | 19 | 11 (55.0) | 8 (44.4) | .52 |
| ≥ 163 | 19 | 9 (45.0) | 10 (55.6) | |
| NL ratio |
| < 3.5 | 22 | 13 (65.0) | 9 (50.0) | .52 |
| ≥ 3.5 | 16 | 7 (35.0) | 9 (50.0) | |
| PNL ratio |
| < 951 | 21 | 14 (70.0) | 6 (38.9) | .05 |
| ≥ 951 | 17 | 7 (30.0) | 12 (61.1) | |
| T status |
| 1–2 | 24 | 16 (60.0) | 8 (44.4) | .02 |
| 3 | 14 | 4 (20.0) | 10 (55.6) | |
| Tumor size (cm) |
| < 2.2 | 18 | 13 (65.0) | 5 (27.8) | .02 |
| > 2.2 | 20 | 7 (35.0) | 13 (72.2) | |
| Node metastasis |
| No | 30 | 19 (65.0) | 11 (61.1) | .01 |
| Yes | 8 | 1 (5.0) | 7 (38.9) | |
| Perineural invasion |
| No | 29 | 17 (58.6) | 12 (66.7) | .18 |
| Yes | 9 | 3 (15.0) | 6 (33.3) | |
| Lymphovascular invasion |
| No | 29 | 18 (62.1) | 11 (61.1) | .04 |
| Yes | 9 | 2 (10.0) | 7 (38.9) | |
| Histologic differentiation |
| Well to moderate | 29 | 16 (55.2) | 13 (72.2) | .57 |
| Poor | 9 | 4 (20.0) | 5 (27.8) | |

CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen, CRP = C-reactive protein, GPS = Glasgow prognostic score, mGPS = modified Glasgow prognostic score, NL = neutrophil-to-lymphocyte, PL = platelet-to-lymphocyte, PNL = platelet-neutrophil-lymphocyte, SUVmax = maximum standardized uptake value, T stage = according to AJCC 7th.
previous reports: the disease recurrence rate was 39%, and the 5-year OS and DFS rates were 70.9% and 62.0%, respectively.\textsuperscript{[19,20]}

There have been reports about various poor prognostic factors, including T category, nodal metastasis, lymphovascular invasion, perineural invasion, blood transfusion, and serum carbohydrate antigen 19-9. Furthermore, systemic inflammatory response has been proven to be closely associated with cancer initiation, promotion, malignant conversion, invasion, and metastasis. Several inflammatory biomarkers, including C-reactive protein (CRP), albumin, PL ratio, NL ratio, and PNL ratio, have been reported using pre-operative blood testing. Cutoff values remain unknown, although all studies agree that a high titer of these biomarkers reflects poor prognosis.\textsuperscript{[21–25]}

NL ratio has been reported as a predictor of prognosis in patients with several types of digestive tract cancers, including esophageal, gastric, colorectal, pancreatic and gallbladder cancer, cholangiocarcinoma, liver metastasis from colorectal cancer, and hepatocellular carcinoma. Haruki et al\textsuperscript{[26]} reported that routine pre-operative NL ratio measurement in patients undergoing curative treatment for ampullary adenocarcinoma may provide a means of identifying patients with poorer prognosis. They demonstrated that a NL ratio $>3$ was an independent and significant predictor of poor OS.\textsuperscript{[27]}

In our study, poor histologic differentiation, high SUVmax, and NL ratio were significant predictive factors associated with patient survival, and poor histologic differentiation and NL ratio were significant predictive factors associated with disease recurrence. NL ratio was an independent predictive factor for both OS and DFS.

Although variations in the uptake of FDG are known to exist among tumor types, an elevated uptake of FDG has been demonstrated in most primary malignancies.\textsuperscript{[28,29]} 18F-FDG PET/CT has been widely used for not only diagnosis of malignancy but also cancer staging, detection of recurrence, and monitoring of treatment. However, in ampullary adenocarcinoma, the clinical effects of 18F-FDG PET/CT have not yet been well-studied, unlike other prognostic factors that have been reported so far. To date, a few studies have reported the clinical usefulness of 18F-FDG PET/CT in the detection and characterization of primary tumor, pre-operative staging, detection of recurrence disease, and response to chemotherapy. Choi et al\textsuperscript{[30]} reported that high SUVmax ($>4.8$) was associated with poor survival outcomes.

In our study, SUVmax ($\geq4.55$) was a significant predictive factor of poor survival. Moreover, we demonstrated that the high metabolism group (SUVmax $\geq4.55$) showed significant correlation with advanced T stage, larger size, lymph node metastasis, lymphovascular invasion, and high PNL ratio. We can assume that these factors influence the outcomes of high metabolic PET/CT activity, which may play an important role in assessing the prognosis of periampullary adenocarcinoma.

Detection of 18F-FDG on PET/CT depends on both the size of the lesion and the degree of uptake, as well as surrounding background uptake and intrinsic resolution of imaging. CRP and hyperglycemia have been reported to be highly associated with detectability.\textsuperscript{[31]} Iwano et al\textsuperscript{[32]} reported that in general, tumor lesions $\leq2$ cm in diameter and well-differentiated carcinomas on thin-section CT images have a tendency toward negative findings on PET scans.

All patients with negative PET findings in our study had small sized tumor below 2.2 cm, lower tumor stage, no node metastasis, and negative lymphovascular invasion. In only 1 case among these patients, the disease recurred despite the absence of poor tumor biology. Another patient with poor tumor biology (poor differentiation and high NL/PNL ratio) showed disease recurrence and eventually died. However, in this case, uneven high levels of CRP were observed. Therefore, small-sized tumor, high level of CRP, and good tumor biology may be the causes of false-negative PET findings (Table 4).

Curative resection is the best option for ampullary adenocarcinoma, but its survival benefit is still compromised by tumor recurrence. Although the efficacy of neoadjuvant treatment has not been proven yet, we can assume that PET/CT may be helpful to select the patients for such a treatment.
that SUVmax of 4.55 on 18F-FDG PET/CT could be a predictive factor for tumor biology and long-term survival in patients with ampullary adenocarcinoma. Nevertheless, considering the procedure cost and limited prognostic effect, further research of this method using larger cohorts and multicenter studies is warranted.

Author contributions

Conceptualization: Hyung Il Seo, Young Mok Park.

Data curation: Hyung Il Seo, Young Mok Park.

Formal analysis: Hyung Il Seo, Young Mok Park.

Funding acquisition: Hyung Il Seo, Young Mok Park.

Investigation: Hyung Il Seo, Young Mok Park.

Methodology: Hyung Il Seo, Young Mok Park.

Project administration: Hyung Il Seo, Young Mok Park.

Resources: Hyung Il Seo, Young Mok Park.

Software: Hyung Il Seo, Young Mok Park.

Supervision: Hyung Il Seo, Young Mok Park.

Validation: Hyung Il Seo, Young Mok Park.

Visualization: Hyung Il Seo, Young Mok Park.

Writing – original draft: Young Mok Park.

Writing – review & editing: Young Mok Park.
References
[1] Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71–96.
[2] Heinrich S, Clavien PA. Ampullary cancer. Curr Opin Gastroenterol 2010;26:280–5.
[3] Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd English edition. J Hepatobiliary Pancreatic Sci 2015;22:181–96.
[4] Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol 2012;105:266–72.
[5] O’Connell JB, Maggard MA, Manungo Jr, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol 2008;15:1820–7.
[6] Choi SB, Kim WB, Song TJ, Suh SO, Kim YC, Choi SY. Surgical outcomes and prognostic factors for ampulla of vater cancer. Scand J Surg 2011;100:92–8.
[7] Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998;228:87–94.
[8] Balci S, Basturk O, Saka B, et al. Substaging nodal status in ampullary carcinomas has significant prognostic value: Proposed revised staging based on an analysis of 313 well-characterized cases. Ann Surg Oncol 2015;22:4392–401.
[9] Chen SC, Shyr YM, Chou SC, Wang SE. The role of lymph nodes in predicting the prognosis of ampullary carcinoma after curative resection. World J Surg Oncol 2015;13:224.
[10] Winter JM, Cameron JL, Olinu K, et al. Clinicopathologic analysis of ampullary neoplasm in 430 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg 2010;14:379–87.
[11] Klein F, Jacob D, Bahra M, et al. Prognostic factors for long-term survival in patients with ampullary carcinoma: the results of a 15-year observation period after pancreaticoduodenectomy. HPB Surg 2014;2014:970234.
[12] Lowe MC, Coban I, Adsay NV, et al. Important prognostic factors in adenocarcinoma of the ampulla of Vater. Am J Surg 2009;197:754–60. discussion 761.
[13] Robert PE, Leux C, Ouassi M, et al. Predictors of long-term survival following resection for ampullary carcinoma: a large retrospective French multicentric study. Pancreas 2014;43:692–7.
[14] Bourgounn S, Ewald J, Mancini J, Moutardier V, Delpero JR, Le Treut YP. Predictors of survival in ampullary, bile duct, and duodenal cancers following pancreaticoduodenectomy: a 10-year multicentric analysis. J Gastrointest Surg 2015;19:1247–55.
[15] Skata J, Shirai Y, Wakai T, Ajikawa Y, Akazawa K, Hatakeyama K. Assessment of nodal status in ampullary carcinoma: the number of positive lymph nodes versus the lymph node ratio. World J Surg 2011;35:2118–24.
[16] Qiao QL, Zhao YG, Ye ML, et al. Carcinoma of the Ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007;31:137–46.
[17] Sudo T, Murakami Y, Uemura K, et al. Prognostic impact of perineural invasion following pancreaticoduodenectomy with lymphadenectomy for ampullary carcinoma. Dig Dis Sci 2008;53:2281–6.
[18] Cho KM, Oh DY, Kim TY, et al. Metabolic characteristics of advanced biliary tract cancer using 18F-Fluorodeoxyglucose positron Emission tomograph and their clinical implications. Oncologist 2015;20:926–33.
[19] Furukawa H, Ikuma H, Ajioka Y, Usaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol 2009;100:494–9.
[20] Kitamura K, Hatano E, Higashi T, et al. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with extrahaepatic bile duct cancer. J Hepatobiliary Pancreat Sci 2011;18:39–46.
[21] Zhu L, Li X, Shen Y, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Onco Targets Ther 2016;9:4879–86.
[22] Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151–9.
[23] Namikawa T, Munekage E, Munekage M, et al. Evaluation of systemic inflammatory response biomarkers in patients receiving chemotherapy for unresectable and recurrent advanced gastric cancer. Oncology 2016;90:321–6.
[24] Dreyer SB, Powell AG, McSorley ST, et al. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Ann Surg Oncol 2017;24:1295–303.
[25] Geng Y, Qi Q, Sun M, Chen H, Wang P, Chen Z. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol 2015;41:1508–14.
[26] Haruki K, Shiba H, Horiuschi T, et al. Neutrophil to lymphocyte ratio predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Anticancer Res 2016;36:403–8.
[27] Dmirci NS, Erdem GU. Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with operable ampullary carcinoma. Bosn J Basic Med Sci 2018;18:268–74.
[28] Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the literature. J Nucl Med 2004;45 (5 Suppl):1S–39S.
[29] Park JS, Yoon DS, Kim KS, et al. Factors influencing recurrence after curative resection for ampulla of Vater carcinoma. J Surg Oncol 2007;95:286–90.
[30] Choi HJ, Kang CM, Jo K, et al. Prognostic significance of standardized uptake value on reoperative 18F-FDG PET/CT in patients with ampullary adenocarcinoma. Eur J Nucl Med Mol Imaging 2015;42:841–7.
[31] Delbeke D, Martin WH. Update of PET and PET/CT for hepatobiliary pancreatic malignancies. HPB (Oxford) 2005;7:166–79.
[32] Iwano S, Ito S, Tsuchiya K, Kato K, Naganawa S. What causes false-negative PET findings for solid-type lung cancer? Lung Cancer 2013;79:132–6.